In light of these challenges, recent studies have shown that combination therapies, such as combining metabolic modulators like formate with anti-PD1, can promote CD8+T cells-mediated tumor control and mouse survival.18 This approach helps to overcome metabolic inhibition in CD8+T cells, promoting better immune activation and tumor clearance. The gene discussed is CD8A; the disease is neoplasm.